<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00720096</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-15042</org_study_id>
    <secondary_id>NFGC 12-12990-01-29</secondary_id>
    <nct_id>NCT00720096</nct_id>
  </id_info>
  <brief_title>Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan</brief_title>
  <official_title>A Pilot Prospective Trial Of Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan In Recurrent Or Persistent Ovarian Cancer Within 12 Months Of Platinum-Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will help us to determine the success of using a special technique called
      microarray technology to examine cancer genes in order to predict how individual women will
      respond to one of two therapies, liposomal doxorubicin or topotecan, and which will be more
      effective in treating ovarian cancer that has returned (recurrent ovarian cancer). We believe
      that this study may lead to a means by which microarray technology can predict the most
      effective treatment decision, based on the genetic characteristics of her tumor tissue, for a
      woman with recurrent ovarian cancer.

      Another purpose of this study is to determine how quickly a woman with recurrent ovarian
      cancer will respond to treatment (treatment response rate) and to evaluate the accuracy of
      the genomic predictions.

      Recent data suggest that microarray technology can predict a patient's response to
      chemotherapy; this has not yet been proven in a forward-looking study which is why we are
      conducting this research.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who take part in the study will have an initial visit and undergo a CT guided core
      biopsy. Using tissue from a CT guided core biopsy, microarray analysis will be performed to
      help predict which of the two drugs appears to be better suited to individual genomic
      factors. The results will result in being assigned to treatment with either liposomal
      doxorubicin or topotecan.

      Patients who receive liposomal doxorubicin - IV chemotherapeutic treatment will occur 3
      times, 28 days apart, weeks 1,5,and 9. At each of these visits patients will be evaluated and
      have blood work to check their liver tests and electrolytes. Every 8 weeks patients will have
      a radiologic evaluation of their tumor.

      Patients who receive topotecan - IV chemotherapeutic treatment will occur 4 times, 21 days
      apart, weeks 1,4,7, and 10. At each of these visits patients will be evaluated and have blood
      work to check levels of liver tests and electrolytes. Every 8 weeks patients will have a
      radiologic evaluation of their tumor.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funds for this project have been spent, and it is thereby terminated.
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess Feasibility</measure>
    <time_frame>1 year, 2 months</time_frame>
    <description>Number of patients meeting 3 week feasibility window which was set as the benchmark.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interpret Genomic Array</measure>
    <time_frame>1 year, 2 months</time_frame>
    <description>Number of patients with biopsiable tumor in sufficient quantity and quality that will result in an interpretable genomic array.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>1 year, 2 months</time_frame>
    <description>Determine response rate of array directed chemotherapy (as defined as the proportion of patients achieving complete or partial responses with a predictive score &gt;/= 0.5 for either chemotherapy). As well as evaluate the accuracy of the chemosensitivity profiles for differentiating doxorubicin and topotecan responsive cancers. Due to the limited sample size the interpretation is limited. Results data for this outcome is not posted.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Liposomal Doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal Doxorubicin - Chemotherapy single agent systemic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topotecan - Chemotherapy single agent systemic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Doxorubicin</intervention_name>
    <description>Liposomal Doxorubicin 40 mg/m2 q 28 days</description>
    <arm_group_label>Liposomal Doxorubicin</arm_group_label>
    <other_name>Doxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>Topotecan (daily x 5 days of a 21 day cycle)
Per amendment #15: Topotecan (days 1, 8, 15 of a 28 day cycle)</description>
    <arm_group_label>Topotecan</arm_group_label>
    <other_name>Hycamtin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have history of histologically or cytologically confirmed epithelial ovarian
             cancer with recurrence.

          -  Must have measurable disease, defined as at least one lesion that can be accurately
             measured in at least one dimension (longest diameter to be recorded) as &gt;20 mm with
             conventional techniques or as &gt;10 mm with spiral computed tomography CT) scan.

          -  May have had only 2 prior chemotherapy regimens, with at least one regimen containing
             platinum, and disease recurrence or progression occurring between 0 to 12 months (1 to
             365 days)from the platinum-containing regimen. Patients who have been treated with
             consolidation treatment are allowed and the consolidation will not be considered a
             separate regimen. Hormonal therapy and immunotherapy will not be considered a prior
             chemotherapy regimen. Hormonal therapies given to treat the patient's cancer should be
             stopped at least 30 days prior to dosing on this trial. Typical low-dose hormone
             replacement therapy to treat postmenopausal symptoms may be continued at the treating
             physician's discretion.

          -  Life expectancy &gt;6 months.

          -  ECOG performance status 2 or less (Karnofsky 60%).

          -  Must have normal organ and marrow function as defined below:

               -  leukocytes 3,000/microL

               -  absolute neutrophil count 1,500/ microL

               -  platelets 100,000/microL

               -  total bilirubin ≤1.5 X institutional upper limit of normal(ULN) aspartate
                  aminotransferase [AST(SGOT)]/alanine aminotransferase [ALT(SGPT)] ≤2.5 X ULN
                  creatinine within normal institutional limits OR creatinine clearance
                  60mL/min/1.73m2 for patients with creatinine levels above institutional normal

          -  Ability to understand and willingness to sign a written informed consent document

          -  Measurable disease on CT must be considered amenable to biopsy by Core methods (core
             biopsy may be radiographically or non-radiographically performed). Potential ability
             to obtain core material must be reviewed by Principal Investigator (PI) and/or his
             designates prior to enrollment.

          -  Must consent to biopsy as part of enrolling into trial.

          -  Patients with reproductive potential must use an adequate contraceptive method (e.g.
             abstinence, intrauterine device, oral contraceptives, barrier device with spermicide
             or surgical sterilization) during treatment and for three months after completing
             treatment.

          -  Must have a Multiple Gated Acquisition (MUGA) scan or 2-d echocardiogram indicating an
             ejection fraction of &gt; 50% or institutional standards within 42 days prior to first
             dose of study drug. The method used at baseline must be used for later monitoring.

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study or those who have not version
             13, 01/10/08 MCC 15042 16 recovered from adverse events due to agents administered
             more than 4 weeks earlier.

          -  May not be receiving any other investigational agents concurrently.

          -  Patients with known brain metastases should be excluded from this clinical trial
             because of their poor prognosis and because they often develop progressive neurologic
             dysfunction that would confound the evaluation of neurologic and other adverse events.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to liposomal doxorubicin or topotecan.

          -  Myocardial infarction within 6 months. History of cardiac disease, with New York Heart
             Association Class II or greater, or clinical evidence of congestive heart failure.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Women who are pregnant.

          -  Women who are breastfeeding should discontinue breastfeeding.

          -  Human Immunodeficiency Virus (HIV)-positive patients receiving combination
             anti-retroviral therapy are excluded from the study because of possible
             pharmacokinetic interactions and increased toxicity.

          -  Patients may have had no other malignancies in the prior 5 years other than
             non-metastatic, locally-controlled, non-melanomatous cutaneous cancers.

          -  Patients who have received radiation to more than 25% of marrow-bearing areas.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert M. Wenham, M.D., M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2008</study_first_submitted>
  <study_first_submitted_qc>July 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2008</study_first_posted>
  <results_first_submitted>October 15, 2010</results_first_submitted>
  <results_first_submitted_qc>January 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 16, 2011</results_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Persistent Ovarian Cancer</keyword>
  <keyword>Genomic directed salvage chemotherapy</keyword>
  <keyword>Genomic Microarray</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liposomal Doxorubicin</title>
          <description>Liposomal Doxorubicin - Chemotherapy single agent systemic.</description>
        </group>
        <group group_id="P2">
          <title>Topotecan</title>
          <description>Topotecan - Chemotherapy single agent systemic.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liposomal Doxorubicin</title>
          <description>Liposomal Doxorubicin - Chemotherapy single agent systemic.</description>
        </group>
        <group group_id="B2">
          <title>Topotecan</title>
          <description>Topotecan - Chemotherapy single agent systemic.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Assess Feasibility</title>
        <description>Number of patients meeting 3 week feasibility window which was set as the benchmark.</description>
        <time_frame>1 year, 2 months</time_frame>
        <population>Patients whose information for treatment was available within the 3 week feasibility window which was set as the benchmark.</population>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Doxorubicin</title>
            <description>Liposomal Doxorubicin - Chemotherapy single agent systemic.</description>
          </group>
          <group group_id="O2">
            <title>Topotecan</title>
            <description>Topotecan - Chemotherapy single agent systemic.</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Feasibility</title>
          <description>Number of patients meeting 3 week feasibility window which was set as the benchmark.</description>
          <population>Patients whose information for treatment was available within the 3 week feasibility window which was set as the benchmark.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interpret Genomic Array</title>
        <description>Number of patients with biopsiable tumor in sufficient quantity and quality that will result in an interpretable genomic array.</description>
        <time_frame>1 year, 2 months</time_frame>
        <population>All patients enrolled 4/4 had biopsiable tumor and sufficient quantity and quality.</population>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Doxorubicin</title>
            <description>Liposomal Doxorubicin - Chemotherapy single agent systemic.</description>
          </group>
          <group group_id="O2">
            <title>Topotecan</title>
            <description>Topotecan - Chemotherapy single agent systemic.</description>
          </group>
        </group_list>
        <measure>
          <title>Interpret Genomic Array</title>
          <description>Number of patients with biopsiable tumor in sufficient quantity and quality that will result in an interpretable genomic array.</description>
          <population>All patients enrolled 4/4 had biopsiable tumor and sufficient quantity and quality.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Biopsiable tumor: sufficient quantity and quality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interpretable data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <description>Determine response rate of array directed chemotherapy (as defined as the proportion of patients achieving complete or partial responses with a predictive score &gt;/= 0.5 for either chemotherapy). As well as evaluate the accuracy of the chemosensitivity profiles for differentiating doxorubicin and topotecan responsive cancers. Due to the limited sample size the interpretation is limited. Results data for this outcome is not posted.</description>
        <time_frame>1 year, 2 months</time_frame>
        <population>Data was not collected for this Pilot study, due to small sample size and early termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Doxorubicin</title>
            <description>Liposomal Doxorubicin - Chemotherapy single agent systemic.</description>
          </group>
          <group group_id="O2">
            <title>Topotecan</title>
            <description>Topotecan - Chemotherapy single agent systemic.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Determine response rate of array directed chemotherapy (as defined as the proportion of patients achieving complete or partial responses with a predictive score &gt;/= 0.5 for either chemotherapy). As well as evaluate the accuracy of the chemosensitivity profiles for differentiating doxorubicin and topotecan responsive cancers. Due to the limited sample size the interpretation is limited. Results data for this outcome is not posted.</description>
          <population>Data was not collected for this Pilot study, due to small sample size and early termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Liposomal Doxorubicin</title>
          <description>Liposomal Doxorubicin - Chemotherapy single agent systemic.</description>
        </group>
        <group group_id="E2">
          <title>Topotecan</title>
          <description>Topotecan - Chemotherapy single agent systemic.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever combined with Anemia</sub_title>
                <description>Topotecan Arm Patient – patient had a hospitalization for Grade 3 neutropenic fever Grade 3 anemia deemed related to Topotecan.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hospital Admission</sub_title>
                <description>Pegylated Liposomal Doxorubicin (PLD) Arm Patient – patient had an SAE of hospital admission for observation due to tumor debulking done of a vaginal lesion that was deemed unrelated.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTC V3</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Infection in blood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ant bite with infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortage of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister on left toe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blister on right toes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blister on right toe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blister on small toe left</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hand foot reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hand foot syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rash (chest)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to limited sample size, we were unable to make definitive conclusions in this trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Wenham, M.D., via Moffitt Cancer Center</name_or_title>
      <organization>H. Lee Moffitt Cancer Center and Research Institute</organization>
      <phone>813-745-4933</phone>
      <email>robert.wenham@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

